Company news

Zentalis Pharmaceuticals, Inc. news in 2023

Zentalis Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

November 5, 2023

Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

August 8, 2023

Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer

July 31, 2023

Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock

June 14, 2023

Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

June 5, 2023

Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting

May 24, 2023

Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations

May 22, 2023

Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

May 9, 2023

Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting

April 25, 2023

Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023

April 16, 2023

Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates

February 28, 2023

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer

February 12, 2023

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

January 31, 2023

Decks in 2023